LifeVantage (NASDAQ:LFVN – Get Free Report) is expected to post its quarterly earnings results after the market closes on Wednesday, February 5th. Analysts expect LifeVantage to post earnings of $0.14 per share and revenue of $67.41 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
LifeVantage Price Performance
LFVN stock opened at $21.16 on Monday. LifeVantage has a 1-year low of $5.22 and a 1-year high of $27.38. The business has a 50 day simple moving average of $18.62 and a two-hundred day simple moving average of $13.32. The company has a market capitalization of $265.03 million, a price-to-earnings ratio of 66.13 and a beta of 0.82.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. Lake Street Capital began coverage on shares of LifeVantage in a research note on Thursday, December 19th. They set a “buy” rating and a $26.00 target price for the company. Craig Hallum assumed coverage on shares of LifeVantage in a report on Tuesday, January 14th. They set a “buy” rating and a $35.00 price objective for the company.
LifeVantage Company Profile
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Further Reading
- Five stocks we like better than LifeVantage
- The How and Why of Investing in Gold Stocks
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- How Investors Can Find the Best Cheap Dividend Stocks
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.
